TAIKO PHARMACEUTICAL CO., LTD. (4574) Stock Price

Taisho Pharmaceutical operates three business segments: pharmaceuticals, infection control, and other businesses. These operations are managed through domestic and international subsidiaries.

In the pharmaceutical business, the company manufactures and sells over-the-counter medicines such as "Seirogan" and "Seirogan Coating A." Products are distributed domestically through pharmacies and drugstores, and internationally through subsidiaries in Hong Kong, China, Taiwan, and other markets.

The infection control business provides products under the "Cleverin" brand, which utilize patented chlorine dioxide technology. These products are sold to a wide range of customers, including general consumers, public institutions, and medical facilities.

The other business segment manufactures and sells bath additives and horticultural wood vinegar made from byproducts generated during pharmaceutical manufacturing. This approach promotes efficient use of resources.

Daiichi Sankyo Pharmaceutical pursues its core principles of "independence," "coexistence," and "creativity," with the mission of meeting essential health and wellness needs in society. Under these principles, the company aims for sustainable growth, prioritizing increases in sales revenue and operating profit. The company also seeks to improve capital efficiency and maximize shareholder returns.

In the pharmaceutical business, self-medication is expected to expand the over-the-counter drug market as Japan's population ages. To meet demand for its flagship product "Seirogan," the company maintains two manufacturing facilities—the Suita and Kyoto plants—to optimize production capacity. In overseas markets, the company is strengthening sales in mainland China, Hong Kong, and Taiwan through deeper partnerships with local distributors.

In the infection control business, the company aims to restore confidence in "Cleverin" by strengthening evidence regarding the effectiveness and safety of chlorine dioxide. To address market uncertainty, the company is tightening cost controls on advertising and marketing expenses to improve profitability.

Financial improvements are progressing through the completion of warrant exercises and asset sales. Beyond improving profitability in the pharmaceutical and infection control businesses, the company is compressing fixed costs through business streamlining to strengthen its earnings structure.